Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
Company to Host Webcast on 12th July at 9am AEST (7pm ET, 11 July) SYDNEY, AUSTRALIA, July 03, 2024 (GLOBE...
Media Release SYDNEY, AUSTRALIA, June 25, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP...
Sydney, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ACN 009 237 889 (ASX: IMM, NASDAQ: IMMP...
Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard...
Media Release Confirmed complete response in a patient with metastatic breast cancer refractory to several...
Media Release Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and...
Media Release First clinical data from the safety lead-in of AIPAC-003 in metastatic breast cancer shows 90mg...
Media Release Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma...
Media Release Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a...
SYDNEY, AUSTRALIA, April 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or...
Data from the safety lead-in of the AIPAC-003 trial shows 90mg efti in combination with paclitaxel is safe and...
Media Release Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall...
Media Release SYDNEY, AUSTRALIA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관
광고 없는 경험을 위해 가입하세요
지금 사용해 보세요
광고 유지